Apellis (APLS) Q1 2025: 4% Injection Growth Masks Channel and Copay Headwinds, Eyes Empaveli Launch

May 7, 2025 | By EarningsIQ Research

Apellis’ Q1 2025 was defined by steady injection growth in geographic atrophy, but headline revenue was pressured by inventory normalization and persistent third-party copay funding gaps. The company’s focus now turns to an anticipated Empaveli label expansion, with commercial execution and payer dynamics in the spotlight as new launches approach.

Summary

• Channel Inventory Reset: Revenue fell short as distributors and physician offices drew down excess inventory built in Q4.
• Copay Funding Friction: Ongoing third-party assistance shortages drove higher sample use, distorting commercial dose metrics and net revenue.
• Launch Pipeline Momentum: Empaveli’s pending C3G and ICMPGN launch is positioned as a near-term catalyst amid steady Sifovri adoption.

Performance Analysis

Apellis’ Q1 performance revealed a business in transition, with topline revenue missing internal expectations despite a 4% quarter-over-quarter increase in Sifovri injection demand. The apparent disconnect stemmed from two non-recurring factors: a drawdown of elevated channel inventory—built up in Q4 following a competitor’s regulatory setback—and a spike in sample usage due to persistent underfunding at third-party copay assistance organizations. Management attributed most of the quarter’s revenue decline to these inventory and funding dynamics, noting that “adjusting Q4 and Q1 for this inventory dynamic, revenue would have been consistent quarter over quarter.”

Underlying demand signals remained constructive: Sifovri maintained over 60% market share in geographic atrophy (GA), and new patient starts exceeded 50% for the first time, reaching 55% by late April. However, the shift to non-revenue-generating samples—about 10,000 doses in Q1, up 5,000 sequentially— muted the translation of demand into recognized revenue. Empaveli’s PNH franchise was stable, but launch momentum is building for the C3G and ICMPGN indications, with a July PDUFA date and strong Phase III data underpinning management’s optimism.

• Inventory Correction: Q1 saw distributors and physician offices normalize stock levels, reversing Q4’s atypical build.
• Sample Utilization Surge: Copay assistance gaps led to doubled sample volumes, impacting revenue by an estimated $10 million.
• GA Market Leadership: Sifovri’s differentiated dosing and efficacy profile continued to win share, despite market and reimbursement headwinds.

Despite headline softness, injection growth and new patient share gains support Apellis’ market leadership in GA, while the company’s pipeline execution offers a meaningful offset to near-term commercial friction.

Executive Commentary

Strategic Positioning

1. Sifovri: Navigating Early-Stage GA Market Adoption

Sifovri, complement C3 inhibitor for geographic atrophy, continues to anchor Apellis’ commercial base, with over 60% market share and new patient starts outpacing competitors. The company’s field team and DTC (direct-to-consumer) initiatives are focused on expanding diagnosis and referral pathways, particularly through optometrist and ophthalmologist education and digital tools that help patients find retina specialists. Management views the GA market as still in its early adoption phase, with significant untapped potential as physicians gain comfort and tools for identifying and treating eligible patients.

2. Copay Assistance and Sample Dynamics: A Double-Edged Sword

Persistent underfunding at third-party copay assistance programs is distorting commercial revenue and increasing reliance on free samples, which do not generate revenue but reflect real patient demand. Apellis is deploying reimbursement education and benefit design support via its Appellis Assist program to help practices transition patients from samples to commercial doses. However, leadership does not expect a near-term resolution to the copay funding gap and is operating under the assumption that the sample/commercial mix will remain elevated for the foreseeable future.

3. Empaveli Launch: Blockbuster Potential in Rare Nephrology

Empaveli, systemic C3 inhibitor, is poised for a major label expansion into C3G and ICMPGN, with a July PDUFA date and strong Phase III data showing a 68% reduction in proteinuria and stabilization of kidney function. The commercial team is executing a targeted prelaunch strategy focused on disease awareness and payer engagement, with the goal of establishing Empaveli as the market leader at launch. Management estimates a U.S. addressable population of 5,000 patients and expects broad adoption based on efficacy rather than route of administration.

4. Cost Discipline and Cash Runway

Following late 2023 cost actions, operating expenses are being tightly managed and are expected to remain flat year-over-year, even as the company invests in new launches. With $358 million in cash and anticipated ex-U.S. royalties, management reiterated confidence in funding the business to profitability, contingent on successful execution of new product launches.

5. Pipeline and Next-Gen Innovation

Apellis is advancing its pipeline with next-generation complement inhibitors, including a combination of intravitreal and systemic siRNA approaches for GA. Management is also planning Phase III studies in additional kidney indications, positioning the company for long-term multi-asset growth.

Key Considerations

Apellis’ Q1 was a microcosm of the challenges facing commercial-stage biotech: growing underlying demand meets real-world friction in reimbursement and channel dynamics. The company’s near-term trajectory will depend on its ability to translate injection growth into revenue, execute a clean Empaveli launch, and manage through persistent funding and market access headwinds.

Key Considerations:

• Inventory and Channel Normalization: Q1’s inventory drawdown appears largely resolved, but ongoing sample use could continue to cloud revenue visibility.
• Copay Assistance Funding Uncertainty: No near-term fix is expected, and Apellis is proactively working to educate practices and transition patients to commercial doses.
• Empaveli Launch Execution: Commercial and medical teams are fully mobilized, with payer and KOL engagement prioritized ahead of the July PDUFA.
• Market Expansion Initiatives: DTC campaigns and optometrist outreach are designed to grow the GA market and drive share gains for Sifovri.
• Cost Control and Profitability Path: Flat operating expenses and a strong cash position support the business through upcoming launches, but revenue conversion remains the key variable.

Risks

Persistent copay assistance underfunding remains a structural risk, potentially capping near-term revenue conversion even as demand grows. Channel inventory fluctuations, while normalized, could recur with market shocks or competitor actions. Tariff exposure, though under review, introduces additional supply chain uncertainty. Finally, Empaveli’s launch success in C3G and ICMPGN will be critical to offsetting any protracted friction in the base GA business.

Forward Outlook

For Q2 2025 and beyond, Apellis guided to:

• Steady Sifovri injection growth, with sample/commercial mix expected to remain at Q1 levels barring a copay funding resolution.
• Operating expenses in line with 2024 levels, reflecting continued cost discipline.

For full-year 2025, management maintained prior guidance:

• Cash runway sufficient to fund the business to profitability, contingent on Empaveli launch and Sifovri demand conversion.

Management highlighted several factors that will shape the outlook:

• Empaveli’s C3G and ICMPGN launch is positioned as a major growth lever for 2H 2025.
• Copay assistance and sample trends are being closely monitored, with ongoing efforts to transition patients to commercial doses.

Takeaways

Apellis’ Q1 underscores the importance of operational agility in the face of external reimbursement shocks and channel volatility. The company’s ability to drive real-world demand, maintain market leadership, and execute upcoming launches will determine whether injection growth ultimately translates to sustainable revenue and margin expansion.

• Revenue Conversion Remains Key: Injection growth is solid, but persistent copay and sample headwinds must be managed to unlock full commercial value.
• Empaveli Launch Is a Defining Catalyst: July’s PDUFA and subsequent launch will test Apellis’ commercial and payer strategy in rare nephrology.
• Market Expansion and Physician Adoption: Early-stage GA market dynamics suggest a long runway for growth as tools, education, and payer access mature.

Conclusion

Apellis delivered robust underlying demand growth in Q1, but translation to revenue was muted by inventory and copay headwinds. With a pivotal Empaveli launch on deck and a disciplined cost base, the company’s near-term outlook hinges on commercial execution and the resolution of external funding friction.

Industry Read-Through

Apellis’ experience this quarter highlights a growing challenge for specialty pharma: reliance on third-party copay assistance is a structural vulnerability, especially as payers and foundations face funding constraints. Channel inventory swings can mask true demand, complicating forecasting and valuation. For the broader biotech sector, successful commercialization now requires not just product differentiation, but also robust market access, reimbursement education, and patient support infrastructure. Companies with pipeline optionality and cost discipline will be best positioned to weather external shocks and capitalize on new launches.

APLS Healthcare Biotechnology Rare Disease Commercial Launch Reimbursement Pipeline Copay